ISSN 1725-2423

Official Journal of the European Union

C 172

Volume 47

English edition

2 July 2004

Information and Notices

Notice No | Contents | Page

EN

I

(Information)

COMMISSION

Euro exchange rates [1]

1 July 2004

(2004/C 172/01)

1 euro =

	Currency	Exchange rate		Currency	Exchange rate
USD	US dollar	1,2168	LVL	Latvian lats	0,6563
JPY	Japanese yen	131,64	MTL	Maltese lira	0,4262
DKK	Danish krone	7,4335	PLN	Polish zloty	4,5005
GBP	Pound sterling	0,6701	ROL	Romanian leu	40 629
SEK	Swedish krona	9,1615	SIT	Slovenian tolar	239,85
CHF	Swiss franc	1,5232	SKK	Slovak koruna	39,845
ISK	Iceland króna	88,43	TRL	Turkish lira	1 791 400
NOK	Norwegian krone	8,441	AUD	Australian dollar	1,7283
BGN	Bulgarian lev	1,9558	CAD	Canadian dollar	1,6172
CYP	Cyprus pound	0,5815	HKD	Hong Kong dollar	9,4907
CZK	Czech koruna	31,875	NZD	New Zealand dollar	1,9013
EEK	Estonian kroon	15,6466	SGD	Singapore dollar	2,0875
HUF	Hungarian forint	251,35	KRW	South Korean won	1 402,54
LTL	Lithuanian litas	3,4529	ZAR	South African rand	7,5203

[1] *Source:* reference exchange rate published by the ECB.

NOTICE OF INITIATION

of a partial interim review of the anti-dumping measures applicable to imports of ammonium nitrate originating in Russia and Ukraine

(2004/C 172/02)

The Commission has received a request for a partial interim review pursuant to Article 11(3) of Council Regulation (EC) No 384/96 [1] ('the basic Regulation').

1. Request for review

The request was lodged by the European Fertilizer Manufacturers Association ('the applicant').

2. Product

The product under review is ammonium nitrate other than in aqueous solution and mixtures of ammonium nitrate with calcium carbonate or other inorganic non-fertilising substances, with a nitrogen content exceeding 28 % by weight, originating in Russia and Ukraine ('the product concerned'), normally classifiable within CN codes 3102 30 90 and 3102 40 90. These CN codes are given only for information.

3. Existing measures

The measures currently in force are a definitive anti-dumping duty imposed by Council Regulation (EC) 132/2001 [2] on imports of ammonium nitrate originating, inter alia, in Ukraine and by Council Regulation (EC) No 658/2002 [3] on imports of ammonium nitrate originating in Russia.

4. Grounds for the review

The applicant has provided information that the scope of the existing measure is no longer sufficient to counteract the dumping which is causing injury.

The applicant alleges that new product types have appeared on the market which should be included in the scope of the measures on the grounds that they share the same basic physical and chemical characteristics and end uses as the product covered by the measures. Both the product concerned and the new product types should therefore be considered as a single product.

5. Procedure for the determination of dumping

Having determined, after consulting the Advisory Committee, that sufficient evidence exists to justify the initiation of a partial interim review, the Commission hereby initiates a review in accordance with Article 11(3) of the basic Regulation, limited in scope to the definition of the product concerned.

The investigation will assess the need for the amendment of the scope of the existing measure.

(a) *Questionnaires*

In order to obtain the information it deems necessary for its investigation, the Commission will send questionnaires to the applicant, to the importers, to the users, to exporting producers in Russia and Ukraine, to the exporters and to the Russian and Ukrainian authorities. This information and supporting evidence should reach the Commission within the time limit set in point 6(a) of this notice.

(b) *Collection of information and holding of hearings*

All interested parties are hereby invited to make their views known, submit information other than questionnaire replies and to provide supporting evidence. This information and supporting evidence must reach the Commission within the time limit set in paragraph 6(a) of this notice.

Furthermore, the Commission may hear interested parties, provided that they make a request showing that there are particular reasons why they should be heard. This request must be made within the time limit set in paragraph 6(b) of this notice.

6. Time limits

(a) *For parties to make themselves known, to submit questionnaire replies and any other information*

All interested parties, if their representations are to be taken into account during the investigation, must make themselves known by contacting the Commission, present their views and submit questionnaire replies or any other information within 40 days of the date of publication of this notice in the Official Journal of the European Union, unless otherwise specified. Attention is drawn to the fact that the exercise of most procedural rights set out in the basic Regulation depends on the party's making itself known within the aforementioned period.

(b) *Hearings*

All interested parties may also apply to be heard by the Commission within the same 40-day time limit.

---

[1] OJ L 56, 6.3.1996, p. 1. Regulation as last amended by Regulation (EC) No 461/2004 (OJ L 77, 13.3.2004, p. 12).
[2] OJ L 23, 25.1.2001, p. 1.
[3] OJ L 102, 18.4.2002, p. 1.

7. **Written submissions, questionnaire replies and correspondence**

All submissions and requests made by interested parties must be made in writing (not in electronic format, unless otherwise specified and must indicate the name, address, e-mail address, telephone and fax, and/or telex numbers of the interested party). All written submissions, including the information requested in this notice, questionnaire replies and correspondence provided by interested parties on a confidential basis shall be labelled as 'Limited' ([1]) and, in accordance with Article 19(2) of the basic Regulation, shall be accompanied by a non-confidential version, which will be labelled 'for inspection by interested parties'.

Commission address for correspondence:

European Commission
Directorate General for Trade
Directorate B
Office: J-79 5/16
B-1049 Brussels
Fax (32 2) 295 65 05
Telex COMEU B 21877.

8. **Non-co-operation**

In cases in which any interested party refuses access to or otherwise does not provide the necessary information within the time limits, or significantly impedes the investigation, findings, affirmative or negative, may be made in accordance with Article 18 of the basic Regulation, on the basis of the facts available.

Where it is found that any interested party has supplied false or misleading information, the information shall be disregarded and use may be made, in accordance with Article 18 of the basic Regulation, of the facts available. If an interested party does not co-operate, or co-operates only partially, and use of the best facts available is made, the result may be less favourable to the party than if it had co-operated.

([1]) This means that the document is for internal use only. It is protected pursuant to Article 4 of Regulation (EC) No 1049/2001 of the European Parliament and of the Council (OJ L 145, 31.5.2001, p. 43). It is a confidential document pursuant to Article 19 of Council Regulation (EC) No 384/96 (OJ L 56, 6.3.1996, p. 1) and Article 6 of the WTO Agreement on Implementation of Article VI of the Gatt 1994 (Anti-dumping Agreement).

Summary of Community decisions on marketing authorization in respect of medicinal products from 15/04/2004 to 15/05/2004

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 ([1]))

(2004/C 172/03)

Issuing of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93) Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
26.04.2004	Velcade	Millenium Pharmaceuticals Ltd Building 3 Chiswick Park 566 Chiswick High Road Chiswick London W4 5YA United Kingdom	EU/1/04/274/001	28.04.2004
28.04.2004	Lysodren	Laboratoire HRA Pharma 19, rue Frédérick Lemaitre F-75020 Paris	EU/1/04/273/001	30.04.2004
28.04.2004	Dukoral	SBL Vaccin AB S-105 21 Stockholm	EU/1/03/263/001-003	03.05.2004

Modification of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93) Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
22.04.2004	Onsenal	Pharmacia-Pfizer EEIG Hillbottom Road High Wycombe Bucks HP12 4PX United Kingdom	EU/1/03/259/001-006	04.05.2004
22.04.2004	Kudeq	Pfizer Limited Sandwich Kent CT13 9NJ United Kingdom	EU/1/02/244/001-024	27.04.2004
22.04.2004	Bextra	Pharmacia-Pfizer EEIG Hillbottom Road High Wycombe Bucks HP12 4PX United Kingdom	EU/1/02/239/001-024	04.05.2004
22.04.2004	Dynastat	Pharmacia Europe EEIG Hillbottom Road High Wycombe Buckinghamshire HP12 4PX United Kingdom	EU/1/02/209/001-008	04.05.2004
22.04.2004	Rayzon	Pharmacia Europe EEIG Hillbottom Road High Wycombe Buckinghamshire HP12 4PX United Kingdom	EU/1/02/210/001-008	04.05.2004

([1]) OJ L 214 du 24 August 1993, page 1.

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
28.04.2004	Zerit	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/96/009/001-017	30.04.2004
28.04.2004	Viracept	Roche Registration Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/97/054/006	30.04.2004
29.04.2004	Stocrin	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom	EU/1/99/111/001-009	07.05.2004
29.04.2004	Sustiva	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/99/110/001-009	04.05.2004
07.05.2004	Ferriprox	Apotex Europe Ltd Rowan House 41 London Street Reading Berkshire RG1 4PS United Kingdom	EU/1/99/108/001	11.05.2004
10.05.2004	Enbrel	Wyeth Europa Limited Huntercombe Lane South Taplow Maidenhead Berkshire SL6 0PH United Kingdom	EU/1/99/126/001-003	12.05.2004
11.05.2004	Cancidas	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom	EU/1/01/196/001-003	13.05.2004
13.05.2004	Cancidas	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom	EU/1/01/196/001-003	17.05.2004

Issuing of a marketing authorization (Article 34 of Council Regulation (EEC) No 2309/93)
Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
07.05.2004	Equilis StrepE	Intervet International BV Wim de Körverstraat, 35 5831 AN Boxmeer Nederland	EU/2/04/043/001	11.05.2004

Modification of a marketing authorization (Article 34 of Council Regulation (EEC) No 2309/93)
Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
28.04.2004	SevoFlo	Abbott laboratories Ltd Queenborough Kent ME11 5EL United Kingdom	EU/2/02/035/001-006	30.04.2004
28.04.2004	Locatim	Biokema Anstalt Aeulestrasse 38 9490 Vaduz Fürstentum Liechtenstein	EU/2/99/011/001	29.04.2004

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Agency for the Evaluation of Medicinal products
7, Westferry Circus, Canary Wharf
LONDON E14 4HB
United Kingdom